Sue D Pedersen
Sue D Pedersen is an expert in Endocrinology at University of Calgary (Canada). As of August 2026, ScienceLeadR ranks Sue D Pedersen in the top 1% of experts worldwide for Obesity, Overnutrition and Overweight. Sue D Pedersen has authored 52 publications, the most recent in 2026, and is an investigator in 16 clinical trials. SLR score: 498 (community average: 125). How the SLR is computed.
LeadR Profile
Endocrinology
Subspecialties: Cardiology - Internal Medicine
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2004 - 2026
Number : 52
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. PMID 42251859 — diabetes mellitus, safety, therapeutics, metformin, diabetes mellitus, type 2, semaglutide | Lancet Diabetes Endocrinol | 2026 | 0 |
| Survodutide Once Weekly for the Treatment of Adults with Obesity. PMID 42253238 — diabetes mellitus, glucagon-like peptide 1, glucagon-like peptide-1 receptor, body weight, obesity, weight loss, glucagon, therapeutics | N Engl J Med | 2026 | 0 |
| Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial. PMID 41879791 — diabetes mellitus, lipoproteins, c-reactive protein, cardiovascular diseases, cholesterol, body weight, risk factors, therapeutics, heart disease risk factors, random allocation, triglycerides, pulse, diabetes mellitus, type 2, semaglutide | JAMA Cardiol | 2026 | 0 |
| Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial. PMID 41627802 — diabetes mellitus, kidney diseases, heart failure, internal medicine, heart, kidney, drug-related side effects and adverse reactions, history, diabetes mellitus, type 2, semaglutide | JAMA Intern Med | 2026 | 0 |
| Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial. PMID 41433034 — diabetes mellitus, hospitalization, cardiovascular diseases, drug-related side effects and adverse reactions, obesity, semaglutide | JAMA Cardiol | 2025 | 0 |
Clinical Studies 16
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
LeadR Networks
Main global connection map